Guangji Pharmaceutical released its 2026 half-year performance forecast, expecting a net loss attributable to shareholders of 51 million to 66 million yuan for the first half, narrowing the loss year-on-year. The company stated that the overall industry market environment has not improved significantly, but through continuous optimization of internal refined operations management and promoting cost reduction and efficiency gains, period expenses during the period decreased significantly compared to the same period last year, while gains from disposal of idle assets increased year-on-year, jointly driving the loss reduction.
Hubei Guangji Pharmaceutical Co LtdCompany expects net loss of 51-66 million yuan in first half, though narrowing year-on-year.